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a b s t r a c t
The henipaviruses, Hendra virus (HeV) and Nipah virus (NiV), are two deadly zoonotic viruses for which
no vaccines or therapeutics have yet been approved for human or livestock use. In 14 outbreaks since 1994
HeV has been responsible for multiple fatalities in horses and humans, with all known human infections
resulting from close contact with infected horses. A vaccine that prevents virus shedding in infected
horses could interrupt the chain of transmission to humans and therefore prevent HeV disease in both.
Here we characterise HeV infection in a ferret model and show that it closely mirrors the disease seen in
humans and horses with induction of systemic vasculitis, including involvement of the pulmonary and
central nervous systems. This model of HeV infection in the ferret was used to assess the immunogenicity
and protective efﬁcacy of a subunit vaccine based on a recombinant soluble version of the HeV attachment
glycoprotein G (HeVsG), adjuvanted with CpG. We report that ferrets vaccinated with a 100 g, 20 g or
4 g dose of HeVsG remained free of clinical signs of HeV infection following a challenge with 5000 TCID50
of HeV. In addition, and of considerable importance, no evidence of virus or viral genome was detected
in any tissues or body ﬂuids in any ferret in the 100 and 20 g groups, while genome was detected in the
nasal washes only of one animal in the 4 g group. Together, our ﬁndings indicate that 100 g or 20 g
doses of HeVsG vaccine can completely prevent a productive HeV infection in the ferret, suggesting that
vaccination to prevent the infection and shedding of HeV is possible.
© 2011 Elsevier Ltd. All rights reserved.

1. Introduction
Hendra virus (HeV) is a zoonotic virus transmitted from bats to
humans via horses. While HeV related disease in bats has not been
documented, the virus can cause a severe systemic illness, with
severe pathology associated with the respiratory and neurological
systems in both horses and humans [1]. Four of the seven human
infections recorded so far have been fatal and the disease is usually
fatal in horses – in the ﬁrst recorded outbreak of HeV in 1994 in
Brisbane, Queensland, Australia 14 horses died out of a total of 20
infected with HeV [2]. Including the initial outbreak there have been
14 known spillovers of HeV and all except one (in northern New
South Wales) occurred in Queensland [3].
HeV is one of only two members of the genus Henipavirus in the
family Paramyxoviridae [4,5]. The henipaviruses are characterised
by a large genome and their ability to infect a wide range of ani-
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mals, including humans. The other member of the genus, Nipah
virus (NiV), was ﬁrst isolated from a disease outbreak that occurred
in Malaysia in 1998 in humans and pigs [6]. Out of 265 human
cases, 105 were fatal. Since 2001 there have been numerous NiV
outbreaks in Bangladesh and two in India [7], the most recent occurrence in early 2011, in Bangladesh [8]. At least two outbreaks have
been associated with virus transmission from human-to-human
[9–11] with both respiratory and neurological signs observed in
humans, and mortality rates ranging from 40% to 75%.
As a result of the potential for henipaviruses to cause signiﬁcant
mortality and morbidity in humans they are classiﬁed as Biosafety
Level 4 (BSL-4) agents. Further, due to their carriage by wildlife and
their relative ease of propagation, the henipaviruses are considered
select agents of concern for biodefense by the Centers for Disease
Control and Prevention (CDC) and the National Institute of Allergy
and Infectious Diseases (NIAID). In spite of this no licensed prophylactic or therapeutic treatments are currently available although
several therapeutic modalities are under active investigation.
Like most paramyxoviruses, henipavirus infection of host cells
involves two viral glycoproteins [12]. The G glycoprotein is the viral
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attachment protein and exists as a tetramer embedded in the lipid
membrane of the virus. Henipavirus G binds to the host cell receptors; ephrin-B2 and ephrin-B3 [13–16], important bi-directional
cell–cell signalling molecules that are highly conserved and widely
expressed particularly within the nervous and vascular systems
[17] across all mammalian species. The second viral glycoprotein is
the fusion (F) protein, which upon triggering facilitates the fusion
between the viral and cellular membranes.
An immune response to viral surface proteins/glycoproteins is
often necessary for resistance to viral infection [18] and is particularly effective in controlling infections with a viraemic phase such
as the human paramyxoviruses that cause mumps and measles
[19,20]. Similarly, passive protection against NiV infection has
recently been demonstrated in a ferret model by transferring a G
glycoprotein speciﬁc, HeV and NiV cross-reactive, human monoclonal antibody [21] and in a hamster model by transferring G or F
glycoprotein speciﬁc polyclonal or monoclonal antibody [22–24]. In
the hamster model, vaccination with recombinant vaccinia viruses
expressing G or F also induced protection against a lethal challenge
with NiV [22]. A similar outcome has been demonstrated in pigs
vaccinated with a canarypox vaccine carrying G or F [25]. In two
different experiments cats vaccinated with a soluble G glycoprotein
(sG) based subunit immunogen survived a lethal NiV challenge with
no clinical signs [26,27]. Although no clinical disease was observed,
in one experiment genome was detected in oral swabs, urine and
the brain of several animals, virus was isolated from the brain of
one animal [26] and in the other experiment genome was detected
in the tissues of two animals at levels that were so low as to be
questionable [27]. There is 83.3% identity between the amino acid
sequences of the HeV and NiV G glycoproteins [28] and it has been
shown that immunisation with sG of either HeV or NiV produces
cross neutralising antibodies, with a better cross neutralisation
response elicited by HeV soluble G (HeVsG) [27]. HeVsG therefore
has potential as a subunit vaccine immunogen for preventing both
HeV and NiV infection.
Previous studies have revealed that ferrets are a very successful
model for NiV infection, closely mirroring the characteristics of the
infection in humans [21,29]. NiV infected ferrets exhibit severe respiratory and neurological disease as well as generalised vasculitis.
Here, we have evaluated HeV infection of ferrets and extend the
use of this new animal model to assess the protective efﬁcacy of
HeVsG as a vaccine immunogen against lethal HeV challenge. We
show that, like NiV, the manifestation of HeV infection and pathogenesis in ferrets is similar to that seen in humans exhibiting both
respiratory and neurological disease. Further, in this model system,
the three HeVsG vaccine doses tested prevented clinical disease
after a lethal HeV challenge, and following the two higher doses of
immunogen there was no detectable evidence of HeV infection.

2. Materials and methods
2.1. Animals, accommodation, handling, and biosafety
Eight male ferrets aged 12–18 months were used for the HeV
model development study and eight were used for the HeVsG vaccination study. The animal husbandry methods and experimental
design were endorsed by the CSIRO Australian Animal Health Laboratory’s Animal Ethics Committee. Animals were housed in a single
room at BSL-4 in pairs in cages that incorporated two “squeeze”
compartments for administration of chemical restraint, given a
complete premium dry food and provided with water ad libitum.
Room temperature was maintained at 22 ◦ C with 15 air changes per
hour; and humidity varied between 40% and 60%. Before any manipulation, animals were immobilized with a mixture of ketamine HCl
(3 mg/kg; Ketamil; Ilium, Smithﬁeld, Australia) and medetomidine

(30 g/kg; Domitor; Novartis, Pendle Hill, Australia) by intramuscular injection. For reversal, atimepazole (Antisedan; Novartis) was
given intramuscularly at 50% of the dose used for medetomidine.
At least one week prior to virus challenge single stage transmitters ﬁtted with an internal loop antenna and coated with an inert
two-pot epoxy resin (Sirtrack, Havelock North, New Zealand) were
implanted subcutaneously in the ﬂank of the ferrets for the purpose
of real-time continuous monitoring of body temperature. Staff wore
fully encapsulated suits with breathing apparatus while in the animal room. Serology, virus isolations, and the initial stages of RNA
extraction were carried out at BSL-4.
2.2. Animal infections
Ferrets were exposed to a low passage isolate of HeV (Redlands 2008) by the oronasal route. For the HeV infection study, 2
ferrets per group were exposed to 50 TCID50 (ferrets 1-50, 2-50),
500 TCID50 (3-500, 4-500), 5000 TCID50 (5-5000, 6-5000) or 50,000
TCID50 (7-50,000, 8-50,000) and for the sG vaccination experiment
ferrets were exposed to 5000 TCID50 at day 41 of the experiment
i.e. 21 days post the booster vaccination.
General clinical observations were documented daily prior to as
well as after challenge. Animals were weighed while under sedation at the time of vaccination and challenge and at days 6, 8, 10, and
21 post-challenge (pc). Rectal temperature was also determined at
sedation by using digital thermometers to augment data derived
remotely from the implanted temperature transponders. Ferrets
were euthanized when reaching a previously determined endpoint
or 21 days pc. The humane endpoint was deﬁned as rapidly progressive clinical illness of up to 2 days duration including fever
and depression, possibly accompanied by increased respiratory rate
or posterior paresis or ataxia. In susceptible animals, this typically
occurs within the ﬁrst 10 days after viral challenge. In preliminary
studies, these signs were found to correlate with the requirement
to euthanize ferrets on subsequent days on humane grounds; thus,
they have been utilized as surrogates for lethality.
2.3. Vaccine immunogen preparation
A human codon optimized HeV soluble glycoprotein G (sG) construct was used to produce recombinant HeVsG. The construct
was generated by cloning the entire ectodomain coding regions
of HeV G linked to an IgK leader sequence and S-peptide tag into
pcDNA CMV+hygro. The expression plasmid pcDNA-CMV+hygro
was generated by insertion of the CMV promoter element from
plasmid phCMV-1(Gelantis, San Diego, CA) into pCDNA3.1(hygro)
(Invitrogen, Carlsbad, CA). A stable HeVsG secreting cell line was
generated by transfecting plasmid pcDNA-CMV+hygro-HeVsG into
human 293F cells and selection using hygromycin B followed
by limiting dilution cloning, generating the cell line HeVsG#4-2
293F. HeVsG was prepared by growing HeVsG#4-2 293F cells in
shaker cultures using serum-free medium- 293 SFM II (Invitrogen)
and puriﬁed by S-protein agarose afﬁnity chromatography followed by preparative gel ﬁltration chromatography with a Hiload
16/60, Superdex 200 column. CpG oligodeoxynucleotide (ODN)
2007 (TCGTCGTTGTCGTTTTGTCGTT) containing a fully phosphorothioate backbone was purchased from Invivogen (San Diego, CA,
USA) and AlhydrogelTM was purchased from Accurate Chemical &
Scientiﬁc Corporation (Westbury, NY, USA). Although the CpG component of the adjuvant is species speciﬁc, in the absence of any
information on ferret speciﬁc CpG sequences the same CpG component was used for the ferret vaccine as was used for cats [26].
Vaccine doses containing ﬁxed amount of CpG ODN 2007 and varying amounts of HeVsG and aluminium ion (at a weight ratio of 1:25)
were formulated as follows: 100 g dose: 100 g HeVsG, 2.5 mg
aluminium ion and 150 g of CpG ODN 2007; 20 g dose: 20 g
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HeVsG, 500 g aluminium ion and 150 g of CpG ODN2007; and
4 g dose: 4 g HeVsG, 100 g aluminium ion and 150 g of CpG
ODN 2007. For all doses, AlhydrogelTM and HeVsG were mixed ﬁrst
before CpG ODN 2007 was added. Each vaccine dose was adjusted
to 1 ml with PBS and mixtures were incubated on a rotating wheel
at room temperature for at least 2–3 h prior to injection.
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2.7. Virus isolation
For virus isolation, supernatants from homogenized tissues positive for HeV genome were incubated on Vero cell monolayers and
scored positive if syncytia, as a measure of viral cytopathic effect,
were present after 6 days.
2.8. Serum neutralisation test

2.4. Immunisation
Ferrets were divided into 4 groups of 2, with each group receiving either a 100 g HeVsG (ferrets 1-100, 2-100), 20 g HeVsG
(ferrets 3-20, 4-20) or 4 g HeVsG (ferrets 5-4, 6-4) dose of vaccine
or adjuvant alone (ferrets 7-0, 8-0). The vaccine was administered
subcutaneously with a priming dose at day 0 and a booster dose 20
days later. Blood samples were collected for antibody analysis at
day 0, day 20 and day 30. Nasal washes, oral and rectal swabs, and
blood samples in EDTA were taken before the ﬁrst vaccination.

2.5. Sample collection
Nasal washes, oral and rectal swabs, and blood samples both in
EDTA and for serum preparation, were taken before challenge and
at days 6, 8, 10 and 21 pc. For the vaccination experiment blood was
taken before challenge as detailed in Section 2.4. Urine was only
collected on day 21 pc due to the tendency of ferrets to urinate on
being woken. Rectal and oral swabs were collected in duplicate into
1 ml of PBS for virus isolation or 800 l of MagMAX Lysis/Binding
solution (Ambion, Victoria, Australia) for genome extraction. For
urine, nasal washes and EDTA blood, 100 l of ﬂuid was added to
260 l Lysis/Binding solution.
At post-mortem (PM) examination, tissues were collected for
virus isolation, viral genome detection, histology and immunohistology. These tissues included adrenal gland, bladder, occipital lobe
of the brain, olfactory pole, heart, kidney, liver, apical lung lobe,
diaphragmatic lung lobe, bronchial lymph node, retropharyngeal
lymph node, spleen and testes. Tissue samples were either collected
into 1 ml of PBS containing 1 mm stainless steel beads (Biospec
Products Inc., Bartlesville, OK, USA) for virus isolation, 800 l MagMAX Lysis/Binding solution containing 1 mm stainless steel beads
for genome extraction, or ﬁxed in 10% neutral buffered formalin for
48 h prior to routine processing for histology. Immunohistochemical evaluation was carried out using a rabbit polyclonal antibody
raised against the NiV N protein [30].

2.6. RNA detection and HeV TaqMan PCR assay
Tissue samples in MagMAX Lysis/Binding buffer were
homogenised for 30 s in a Mini-Beadbeater (BioSpec Products
Inc.) and centrifuged to pellet debris. 260 l of homogenised
sample was then extracted using the MagMAX-96 viral RNA isolation kit (Ambion). TaqMan real-time PCR was carried out using
the AgPath-ID one-step reverse transcription-PCR kit (Applied
Biosystems, Victoria, Australia), targeting the N gene of HeV
using primers FOR (5 -GATATITTTGAMGAGGCGGCTAGTT-3 ),
REV (5 -CCCATCTCAGTTCTGGGCTATTAG-3 ), and probe (6FAMCTACTTTGACTACTAAGATAAGA-MGB). Positive results were
deﬁned by a cycle threshold (CT) value of <40 [31]. Relative
quantiﬁcation of viral RNA levels in the tissues of each animal
relative to the occipital lobe of the brain was performed using the
comparative CT or CT method [32]. The occipital lobe of the
brain was chosen as the reference tissue because the relatively
low viral RNA load meant that most tissues carried relatively more
viral RNA, making a graph of the results easier to interpret.

Serial doubling dilutions of sera were carried out (ﬁnal volume
50 l/well) to which 50 l HeV (100 TCID50 ) was added and incubated for 1 h at 37 ◦ C. Following incubation 100 l Vero cells at
2 × 105 -cells/ml was added to each well and the assay was read
after 3 days incubation in a humidiﬁed 5% CO2 incubator.
2.9. Measurement of antibody to HeV F glycoprotein in ferret
serum
Recombinant expressed HeV sF (Chan and Broder, in preparation for publication) was coupled to microspheres and multiplexed
microsphere assays were performed essentially as previously
described [33]. A LuminexH 100 ISTM machine and MiraiBio software (MiraiBio Group, South San Francisco, CA) were utilized for all
assays: Bio-Plex Manager software (Bio-Rad Industries, Hercules,
CA) for acquisition and analysis. All samples were assayed simultaneously and concentrations were extrapolated from a standard
curve using non-linear regression analysis (GraphPadSoftware, San
Diego, CA).
3. Results
3.1. HeV infection in ferrets
Ferrets have been shown to be acutely sensitive to NiV infection and pathogenesis [21,29]. The purpose of developing the HeV
ferret model here was to determine the predicted susceptibility of
these animals to HeV challenge and HeV-mediated pathogenesis
and to derive a challenge dose of HeV that would reliably infect
susceptible animals, induce disease that would be expected to be
lethal without other intervention, and could be applied to subsequent vaccine and therapeutic studies. Ferrets in the different dose
groups 1-50, 2-50, 3-500, 4-500, 5-5,000, 6-5,000, 7-50,000 and 850,000 were all infected and all ferrets reached a humane endpoint
and were euthanized from days 6 to 9 pc. There was no association
of virus dose with incubation time, clinical signs, time to endpoint,
and either distribution or severity of gross or histopathological
lesions. Fever was established in all animals by day 6 pc, and clinical signs included depression, lack of grooming, and generalised
tremors. At post mortem examination, there was subcutaneous
edema of the head and neck, cutaneous petechiation, numerous 1 mm slightly hemorrhagic nodules scattered throughout the
parenchyma of the lung, together with marked hemorrhage of
submandibular, bronchial, duodenal and mesenteric lymph nodes.
On histologic examination ferrets showed systemic vasculitis,
necrotising lymphadenitis, glomerulitis, splenitis and bronchoalveolitis with syncytial cell formation. HeV antigen was identiﬁed in
meningeal endothelial cells (Fig. 1A and B), lymphatic, glomerular, splenic, pulmonary, cardiac, testicular, pancreatic and intestinal
endothelial cells as well as bronchoalveolar epithelium (Fig. 1C).
3.2. HeV genome detection and virus isolation from infected
ferrets
Thirteen different tissues from each of the 8 ferrets were
screened for the presence of HeV RNA as were oral and rectal swabs,
urine and blood. RNA was detected in all tissues tested from each

5626

J. Pallister et al. / Vaccine 29 (2011) 5623–5630

Fig. 1. Immunohistology using rabbit polyclonal anti-Nipah N protein. (A and B) demonstrating antigen in endothelium of meningeal blood vessels of ferrets 7 and 9 days post
exposure to 5000 TCID50 HeV (ferrets 5-5000 and 6-5000) and also (C) associated with acute necrotising alveolitis in ferret 6-5000 at 9 days post infection. (D) Post-challenge
acute renal tubular necrosis not attributed to HeV in ferret 5-4 immunised with 4 g HeVsG vaccine (Hematoxylin & eosin). Scale bar = 100 m.

ferret. On average, for the 8 animals the lowest relative Ct level and
highest proportion of virus isolations was in the kidney, lung and
spleen. Positive virus isolations were made in these tissues from all
8 ferrets. The highest relative Ct level and the lowest level of virus
isolation were observed in the occipital lobe of the brain, olfactory
pole and the heart (Fig. 2). Virus was isolated from the occipital lobe
at PM (day 9 pc) in ferret 1-50; from the olfactory pole at day 6 pc
in ferret 4-500, at PM (day 9 pc) in ferret 1-50 and at PM (day 7 pc)
in ferret 8-50,000; from the heart at PM (day 9 pc) in ferret 1-50.
For each sampling day genome was detected in all oral and rectal
swabs, blood samples and in the 7 urine samples collected at post
mortem (there was no urine sample from 2-50 at PM). However,
the only virus isolations were from 3 urine samples at PM (day 7
pc) from ferrets 5-5000, 7-50,000 and 8-50,000, one blood sample
at day 6 pc from ferret 2-50 and one rectal swab at PM (day 8 pc)
from ferret 3-500.

3.3. Immunisation
No reactions such as swelling or erythema were identiﬁed at
vaccine sites. At the time of the booster vaccination at day 20, neutralising titres in sera correlated to the dose of sG administered;
ranging from a titre of 8192 for the 100 g vaccination group, to
1024/2048 for the 20 g vaccination group, and 64/128 for the 4 g
vaccination group (Table 1). A greater rise in SNT titre was noted at
day 30 following the booster immunizations in the lower antigen
groups, and the lack of a measurable rise in SNT titre in the 100 g
vaccination group was likely due to the larger amount of antigen
used in the ﬁrst immunization and the timing of the booster immu-

nization. Prior to challenge, neutralising titres in all 6 vaccinated
animals were 8192 or greater.
3.4. Hendra virus challenge of immunized ferrets
Ferrets in the vaccination and challenge study were inoculated
with a low passage isolate of HeV (Redlands 2008) by oronasal
administration. Based on the outcome of the minimal infectious
dose experiment we chose a 5000 TCID50 dose (100 times the minimal lethal dose observed) administered at 21 days post booster
vaccination. Control ferrets vaccinated with adjuvant only and subsequently challenged with HeV (ferrets 7-0 and 8-0) became febrile
(>40 ◦ C) on day 5 pc, showed reduced play activity and hind limb
paresis, and were euthanized on day 7 pc. All HeVsG immunised
ferrets including the 100 g dose group (ferrets 1-100, 2-100), the
20 g dose group (ferrets 3-20, 4-20) and one of the 4 g dose group
Table 1
HeV serum neutralisation titres from HeVsG vaccinated and control ferrets prior to
challenge.
Ferret # – dose HeVsG

1-100
2-100
3-20
4-20
5-4
6-4
7-0
8-0

HeV SNT titre
Day 0

Day 20

Day 30

<1:2
<1:2
<1:2
<1:2
<1:2
<1:2
<1:2
<1:2

1:8192
1:8192
1:1024
1:2048
1:64
1:128
<1:2
<1:2

1:8192
1:8192
1:8192
1:16384
1:8192
1:8192
<1:2
<1:2
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Fig. 2. Relative abundance of HeV genome in different tissues for the HeV Redlands dose titration. The values obtained for the tissue from the occipital lobe of the brain are
used as the calibrator, and quantiﬁcation is relative to this tissue type in each animal. Boxed areas below the axis represent tissues where relatively less genome was detected
than in the occipital lobe of the brain animal numbers and tissue are indicated along the x-axis. (A) Adrenal gland, bladder, brain-olfactory node, heart, kidney and liver. (B)
Lymph nodes-bronchial, lymph nodes-retro pharyngeal, lung-apical node, lung-diagphragmatic node, spleen and testes. Numbering along the axis indicates the challenge
dose groups. Two ferrets per group were exposed to 50 TCID50 (numbers 1 and 2), 500 TCID50 (numbers 3 and 4), 5000 TCID50 (numbers 5 and 6) or 50,000 TCID50 (numbers
7 and 8).

(ferret 6-4) remained afebrile and clinically well throughout the
study. The single low dose animal ferret 5-4 also remained afebrile
but showed reduced play activity on day 9 pc, developed weakness
and tremor and was euthanized on day 10 pc.

3.5. Virus isolation and genome detection
Virus isolation and genome detection are shown in Table 2. Viral
genome was detected in most tissues and ﬂuids from control ferrets and virus was isolated from a number of, but not all, genome
positive samples. In contrast, HeV genome was not detected in any
of the tissues from the HeVsG immunised animals, including those
from ferret 5-4 which was euthanized at d10 pc. HeV genome was
not detected in the body ﬂuids of HeVsG immunised ferrets except
in nasal washes taken at day 6, 8 and 10 pc from ferret 6-4, with Ct
values ranging from 35.2 to 37.2. Both of the unvaccinated control
ferrets, 7-0 and 8-0, were euthanased at day 7 pc and genome was
detected in the nasal washes of 8-0 at this time. Virus isolation from
ferret 6-4 nasal washes was unsuccessful.

3.6. Post-challenge serology
Control ferrets 7-0 and 8-0 were negative for serum neutralising
antibody at day 6 pc and at euthanasia (day 7 pc). No signiﬁcant or
consistent rise in antibody titre was detected post-challenge in any
HeVsG immunised ferrets (Table 3).

3.7. Gross pathology, histopathology and immunohistochemistry
Similar gross and histopathological lesions were observed in
control ferrets 7-0 and 8-0 to those found in animals used for development of the infection model described above (Fig. 1). All other
ferrets apart from ferret 5-4 were grossly and histologically normal. In ferret 5-4, both kidneys were pale and enlarged and the
stomach contained hemorrhagic ﬂuid. Histologically, acute renal
tubular necrosis was identiﬁed that was not attributable to HeV
infection in this animal (Fig. 1). No HeV antigen was detected in
any tissue of HeVsG immunised ferrets.
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Table 2
Genome detection and virus isolation from HeVsG vaccinated and control HeV challenged ferrets.
TaqMan real time PCR
Ferret #

Eut (dpc)

1-100
2-100
3-20
4-20
5-4
6-4
7-0

21
21
21
21
10
21
7

8-0

7

Swabs
Or

Re

−
−
−
−
−
−
+
d6,7
+
d7

−
−
−
−
−
−
+
d7
+
d7

Virus isolation

Nasal wash

Blood

Urine

Tissues

Swabs
Or
Re

Nasal wash

Blood

Urine

Tissues

−
−
−
−
−
+ d6,8,10
−

−
−
−
−
−
−
+
d6,7
+
d6,7

−
−
−
−
−
−
+
d7
+
d7

−
−
−
−
−
−
13/13 +ve

−
−
−
−
−
−
−

−

−
−
−
−
−
−
−

−
−
−
−
−
−
−

−
−
−
−
−
−
−

−
−
−
−
−
−
7/13 +ve

12/13 +ve

+
d7

−

−

−

+
d7

5/13 +ve

+
d7

Ferret # also indicates dose of HeVsG in g, Eut (dpc) indicates day post challenge that ferrets were euthanized. Swabs: Or = oral swabs, Re = rectal swabs. − indicates no viral
genome detected/no virus isolated; + indicates viral genome detected/virus isolated, with the days on which genome or virus was detected. For tissues ‘+ve’ indicates the
number of positive tissues from the 13 tissues analysed.

Table 3
HeV serum neutralisation titres from HeVsG vaccinated and control ferrets post-challenge.
Ferret # and g dose HeVsG

1-100
2-100
3-20
4-20
5-4
6-4
7-0
8-0

HeV SNT titre
Day 30 pv

Day 6 pc

Day 8 pc

Day 10 pc

Day 21 pc

1:8192
1:8192
1:8192
1:16384
1:8192
1:8192
<1:2
<1:2

1:2048
1:1024
1:512
1:4096
1:2048
1:1024
<1:2
<1:2

1:4096
1:512
1:512
1:512
1:512
1:128
ND
ND

1:1024
1:4096
1:128
1:512
ND
1:512
ND
ND

1:512
1:1024
1:2048
1:8192
1:512
1:256
<1:2
<1:2

SNT = serum neutralisation titre, pv = post vaccination, pc = post challenge.

3.8. Measurement of antibody to HeV F glycoprotein in ferret
serum
As an indirect, alternative measure of virus replication in vaccinated animals, antibody to the HeV F glycoprotein was measured
in sera using a Luminex microsphere assay (Fig. 3). The only source
of the F glycoprotein in this experiment is the live viral challenge
at day 41 of the experiment. Prior to challenge ferrets are exposed
to HeVsG alone (except ferrets 7-0 and 8-0) therefore MFI values
obtained up to day 41 represent those we ﬁnd in sera from ferrets with no exposure to F glycoprotein. At the time of euthanasia,
three weeks after challenge, MFI values in all 8 ferrets had not
risen above those obtained prior to challenge, indicating that we
were not detecting antibody to the F glycoprotein. From this we
inferred that the challenge virus had not replicated. Antibody to

Fig. 3. Luminex assay showing no increase in detection of antibody to HeV F
glycoprotein in serum after challenge with HeV at day 40. M.F.I. indicates mean
ﬂuorescence intensity. Ferret number on the x-axis also indicates dose of HeVsG
in g. PM (day of post mortem) varies. Both control ferrets (7-0 and 8-0) were
euthanased at day 7 pc, ferret 5-4 was euthanased at day 10 pc. Remaining ferrets
were all euthanased at d 21 pc.

HeV F glycoprotein was not detected in the virus controls but these
animals were euthanized at d7 pc, before detectable antibody could
develop.

4. Discussion
All known human cases of infection with HeV to date have
resulted from close contact with infected horses, with no recorded
instances of bat to human or human-to-human transmission [28].
These observations make the horse an attractive target for a
HeV vaccination strategy to prevent virus shedding from infected
horses, with the resulting interruption of the principal chain of
transmission of HeV to humans preventing HeV disease in both.
There are currently no licensed vaccines available for prevention
of henipavirus disease. However, trials of various henipavirus vaccine candidates in three different animal models – cats, hamsters
and pigs [22,25–27] indicate that a successful vaccination strategy
against disease caused by HeV and NiV should be possible.
Here we assessed the suitability of the ferret as a model for (i)
infection with HeV and the resultant virus-induced disease and
(ii) vaccination against the disease caused by HeV. Ferrets fulﬁl
some important requirements for working with a BSL-4 pathogen.
Compared to hamsters they are large enough to allow more sophisticated sampling interventions to be carried out on individual
animals over the time course of an infection, they are easier to
handle than pigs and cats, and develop disease much more reliably than pigs. Ferrets have been successfully used to model other
human respiratory infections such as inﬂuenza [34] and SARS [35]
as well as NiV [21,29]. Similarly to NiV, exposure of ferrets to a relatively low challenge dose of HeV consistently results in all animals
developing an acute, fulminating systemic infection characterised
by wide-spread vasculitis and affecting multiple major organ systems particularly the lung and central nervous system.
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Using this ferret model of HeV infection and pathogenesis we
evaluated an immunization strategy with a subunit vaccine based
on recombinant HeVsG. As observed in a feline model of NiV challenge [27], a 100 g dose of HeVsG successfully prevented clinical
disease with no evidence of viral replication or shedding as detected
by TaqMan real-time PCR, virus isolation, histology or immunohistology. In addition, virus infection, replication and shedding was
also prevented in ferrets in the 20 g and 4 g dosing groups of the
HeVsG immunogen, with the exception of one animal in the low
dose group. Here, genome was detected in the nasal washes of this
animal (ferret 6-4) at three consecutive sampling times up to day
10 pc. Importantly, as viral genome was not detected in the nasal
washes of any other ferret this is consistent with viral replication
rather than detection of the original inoculum. No HeV genome
was detected in any other tissue or body ﬂuid of this ferret, nor did
the ferret exhibit any signs of illness, indicating that the immune
response generated by the 4 g vaccine dose was sufﬁcient to limit
infection to the primary site of exposure. Prevention of virus replication was also supported by the lack of an anamnestic antibody
response to the virus challenge as well as the absence of an antibody
response to HeV F glycoprotein in any of the vaccinated ferrets 21
days after challenge.
In a similar experiment, cats immunised with 5, 25 and 50 g
HeVsG vaccine and challenged with NiV showed evidence of viral
replication with increasing antibody titres post challenge and
genome detection in oral swabs, urine and the brains of 4 animals
receiving two higher doses of vaccine [26]. The detection of viral
genome in the brain of cats with signiﬁcant antibody levels prior to
challenge indicated that a persistent infection might occur despite
pre-existing immunity. A farmer infected during the ﬁrst recorded
outbreak of HeV that occurred in Mackay in August 1994 recovered
from meningitis only to develop neurologic signs 14 months later
and die with HeV present in the brain [36].
Variation in vaccination regimes, adjuvants used, the challenge
virus stock and dose do not allow for an absolute direct comparison
between any of the recombinant HeVsG vaccination trials carried
out to date. However, these various trials clearly indicate that vaccination with HeVsG can prevent clinical HeV disease, and in some
cases HeV infection, depending on the trial parameters as seen in
at least two animal models. Prevention of infection is vital for preventing the establishment of a persistent infection from which virus
could recrudesce some time after recovery. Also of similar importance, especially in the case of a vaccination scenario for horses,
the prevention of infectious virus shedding could be considered a
critical goal, and our ﬁndings here indicate that the higher doses
of at least 20 g was able to meet this standard. Future studies are
planned to assess the recombinant HeVsG vaccination strategy in
ferrets further, as well as assess the performance of the vaccine in
non-human primates and in horses.
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